Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
Eugene D. Kwon(Mayo Clinic), Charles G. Drake(Sidney Kimmel Comprehensive Cancer Center), H. I. Scher(Memorial Sloan Kettering Cancer Center), Karim Fizazi(Université Paris-Sud), Alberto Bossi(Institut Gustave Roussy), Alfons J.M. van den Eertwegh(Amsterdam UMC Location Vrije Universiteit Amsterdam), Michael Krainer(Vienna General Hospital), Nadine Houédé(Centre Hospitalier Universitaire de Nîmes), Ricardo Vieira Santos, Hakim Mahammedi(Centre Jean Perrin), Siobhan Ng(St John of God Subiaco Hospital), Michele Maio(University of Siena), Fábio Franke, Santhanam Sundar, Neeraj Agarwal(University of Utah), Andries M. Bergman(The Netherlands Cancer Institute), Tudor–Eliade Ciuleanu(Institute of Oncology Prof. Dr. Ion Chiricuta), Ernesto Korbenfeld(Hospital Británico de Buenos Aires), Lisa Sengeløv(Herlev Hospital), Steinbjørn Hansen(Odense University Hospital), C. Logothetis(The University of Texas MD Anderson Cancer Center), Tomasz M. Beer(Oregon Health & Science University), M. Brent McHenry(Bristol-Myers Squibb (United States)), Paul Gagnier(Bristol-Myers Squibb (United States)), David Liu(Bristol-Myers Squibb (United States)), Winald R. Gerritsen(Radboud University Nijmegen)
Cited by 1,490Open Access
Abstract
Related Papers
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Philip W. Kantoff, Celestia S. Higano, Neal D. Shore et al.|New England Journal of Medicine|2010|5.5k
Counting Processes and Survival Analysis.
Dorota M. Dabrowska, Thomas R. Fleming, David P. Harrington|Journal of the American Statistical Association|1992|2.3k